Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?
Executive Summary
Coherus refutes Apotex argument that Neulasta biosimilars must be studied in at least one patient population. Its application could face delay as no advisory committee meeting has been scheduled ahead of its June 9 user fee date.